Skip to main content

Table 3 Treatment and Patient Outcomes

From: Acromegaly: a clinical perspective

Factor Total
(N = 136)
n n (%)
Preoperative medical treatment 134 84(62.7)
 • Octreotide 84 68(80.9)
 • Lanreotide 84 6(7.1)
 • Bromocriptine 84 1(1.2)
 • Cabergoline 84 2(2.4)
 • Pegvisomant 84 0
 • Octreotide + Bromocriptine 84 1(1.2)
 • Octreotide + Cabergoline 84 4(4.8)
 • Octreotide + Pegvisomant 84 2(2.4)
Transsphenoidal surgery 136 135(99.3)
Craniotomy required 132 7(5.3)
Initial complete resection 135 87(64.4)
Repeat surgery 136 19(14.0)
Irradiation 135 27(20.0)
Medication initiated after surgery 136 65(47.8)
 • Somatostatin analog (SSA) 65 32(49.2)
 • Dopamine agonists (DA) 65 3(4.6)
 • Pasireotide 65 0
 • Pegvisomant (PEG) 65 1(1.5)
 • Combination SSA + DA 65 8(12.3)
 • Combination SSA + PEG 65 7(10.8)
 • Combination DA + PEG 65 2(3.1)
 • Sequential SSA + DA + PEG 65 11(16.9)
 • Sequential SSA + DA + PEG + Pasireotide 65 1(1.5)
Response to surgery 87 61(70.1)
Response to medication and/or radiation: 65 31(47.7)
Hypopituitarism 133 22(16.5)
Improvement of symptoms after treatment 118 108(91.5)
Improvement of comorbidities after treatment 87 60(69.0)